Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Simon J Harrison, Aurore Perrot, Adrian Alegre, David Simpson, Ming Chung Wang, Andrew Spencer, Sosana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Facon, Philip Vlummens, Kwee Yong, Frank Campana, Marlene Inchauspe, Sandrine Mace, Marie-Laure Risse, Helgi Velde, Paul Richardson
BRITISH JOURNAL OF HAEMATOLOGY | WILEY | Published : 2021
Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal. The phase 3 ICARIA-MM trial (NCT02990338) showed that isatuximab plus pomalidomide-dexamethasone prolongs median progression-free survival (mPFS) in patients with relapsed/refractory MM (RRMM). This subgroup analysis of ICARIA-MM compared the benefit of isatuximab in high-risk [defined by the presence of del(17p), t(4;14) or t(14;16)] versus standard-risk patients. The efficacy of isatuximab in patients with gain(1q21) abnormality was also assessed in a retrospective subgroup analysis. In ICARIA-MM, 307 patients received isatuximab-pomalidomide-dexamethasone (n = 154) or pomalidomide-dexametha..View full abstract
The ICARIA-MM study was sponsored by Sanofi. The authors thank the participating patients and their families, and the study centres and investigators, for their contributions to the study. We thank Solenn Le Guennec for her contributions to the statistical analysis. Medical writing support was provided by Stephanie Brillhart and Smitha Reddy of Elevate Medical Affairs (Fairfield, CT, USA), and funded by Sanofi (Cambridge, MA, USA).